Oncothyreon granted Braeburn rights to develop and commercialize ATI-9242, a next-generation atypical antipsychotic agent modeled on clozapine that has completed a Phase I trial to treat schizophrenia. Braeburn plans to develop ATI-9242 into a long-acting...

ARYx reduced headcount to fewer than 20 and hired Cowen and Co. to explore strategic options after partnering discussions for budiodarone fell through. The anti-arrhythmic amiodarone analog has completed a Phase IIb trial to treat...

There some indications where it is hard to get new drugs approved, despite the obvious need, because patients on traditional treatments do so much better in the rigorous setting of a clinical trial than they...

ARYx began a double-blind, placebo-controlled Phase I (CLN-901) trial of oral ATI-9242 in healthy volunteers. ARYx Therapeutics Inc. (NASDAQ:ARYX), Fremont, Calif.   Product: ATI-9242   Business: Neurology   Molecular target: NA   Description: Next-generation atypical...

Although big series A rounds have become increasingly commonplace, the recent deal for Albireo AB, expected to reach $40 million, reflects business as usual for Nomura Phase4 Ventures. The London firm has taken an aggressive...